1. Home
  2. NANOW vs CRDL Comparison

NANOW vs CRDL Comparison

Compare NANOW & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NANOW

Forge Nano Holdings Inc. Warrants

N/A

Current Price

$0.49

Market Cap

104.9M

Sector

Technology

ML Signal

N/A

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$0.88

Market Cap

123.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NANOW
CRDL
Founded
N/A
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.9M
123.9M
IPO Year
2026
2017

Fundamental Metrics

Financial Performance
Metric
NANOW
CRDL
Price
$0.49
$0.88
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $8.41
AVG Volume (30 Days)
68.6K
★ 492.9K
Earning Date
N/A
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$0.88
52 Week High
$0.85
$2.34

Technical Indicators

Market Signals
Indicator
NANOW
CRDL
Relative Strength Index (RSI) 34.09 25.86
Support Level N/A N/A
Resistance Level $0.77 $1.09
Average True Range (ATR) 0.10 0.07
MACD -0.02 0.01
Stochastic Oscillator 11.91 5.92

Price Performance

Historical Comparison
NANOW
CRDL

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: